

University of Groningen

## New frontiers in bronchoscopic lung volume reduction for the treatment of severe emphysema

Roodenburg, Sharyn Aranka

DOI:

[10.33612/diss.1069446755](https://doi.org/10.33612/diss.1069446755)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2024

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Roodenburg, S. A. (2024). *New frontiers in bronchoscopic lung volume reduction for the treatment of severe emphysema*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.1069446755>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.


*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

CHAPTER  
**10**

Endobronchial valve treatment  
does not cause significant nickel  
deposition in lung tissue

Sharyn A. Roodenburg  
Simon D. Pouwels  
Karin Klooster  
Daan J. Touw  
Dirk-Jan Slebos

Adapted from *Respiration*. 2023;102(6):454-457  
DOI: 10.1159/000529889



## ABSTRACT

Bronchoscopic lung volume reduction using endobronchial valves (EBVs) is a treatment option for patients with severe emphysema. These EBVs are made out of nitinol mesh covered by a silicone layer. Nitinol is an alloy of nickel and titanium and is commonly used in implantable medical devices, because of its biocompatibility and memory-shape properties. However, there are some concerns that nickel ions can be released from nitinol-containing devices which might cause adverse health-effects, especially in patients with a known nickel hypersensitivity. In vitro it was found that EBV release significant amounts of nickel in the first hours. Our aim was to assess the nickel concentration in lung tissue from a patients who previously underwent EBV treatment, but due to treatment failure, underwent lung volume reduction surgery (LVRS) and to compare this to a reference sample. We found no significant difference in the median nickel concentration between the EBV patient and the non-EBV patient (0.270 vs 0.328  $\mu\text{g/g}$ , respectively,  $p = 0.693$ ), and also were comparable to previously published nickel concentrations in human lung tissue samples not having medical devices. Our results suggest that there is no significant long-term nickel deposition in lung tissue after EBV treatment.

## INTRODUCTION

Bronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBVs) is a treatment option for a selected group of patients with severe emphysema. Clinically meaningful improvements in pulmonary function, exercise capacity, and quality of life are reported after treatment [110]. The most frequently used EBV is the Zephyr EBV (PulmonX Inc., Redwood, CA, USA) which consists of a circular mesh made of nitinol, a metal alloy of nickel and titanium, covered with a thin silicone layer.

Because of its biocompatibility, corrosion resistance, and memory-shape properties, nitinol is a commonly used compound in implantable medical devices [182]. Nitinol is composed of approximately 54.5-57% nickel by weight percent [182, 183]. Nickel is known as the most common metal sensitizer and therefore the use of nitinol in medical implantable devices raises the concern of nickel ion release which might lead to adverse health effects, especially in nickel-sensitized individuals [183].

Release of nickel ions from nitinol implants has been studied with Amplatzer septal occluders, cardiac implants used to close atrial septal defects. Several studies, both in vitro and in vivo have shown that these implants release nickel ions [184-186]. However, it remains unclear if there is a cause-effect relation between this release and the occurrence of complications or if this release has any clinical relevance in general. The amount of nickel ions that are released from EBVs might be different from other nitinol devices, as the amount of nickel that leaches from a device is dependent on multiple factors related to the manufacturing process and the environment in which the device is implanted [182, 183]. Furthermore, the nitinol frame of EBVs is mostly covered by silicone, preventing nickel ion release, which is not the case with Amplatzer septal occluders. However, it has been shown that the surface area of the EBV is not always completely covered with silicone [187, 188].


To date, only one in vitro study has assessed the release of nickel ions from EBVs. This study found a significant release of nickel in the first 48 hours, which did remain below the toxic level (for oral intake of nickel) [187]. However, it remains unknown if these results resemble the in vivo situation especially because the implantation environment can influence the amount of nickel that can leach from nitinol devices. Therefore, we assessed the nickel concentration in surgically removed lung tissue from a patient previously treated with EBVs and compared this to the nickel concentration in lung tissue from a control sample (non-EBV patient) and nickel concentrations in lung tissue reported in the literature.

## CASE REPORT

Our EBV lung tissue sample was retrieved from a 63-year old female COPD patient with predominately lower lobe emphysema. She had a pre-treatment FEV<sub>1</sub> of 29% of predicted, residual volume (RV) of 230% of predicted, and 6-minute walk distance (6MWD) of 404 meters, and was treated with EBVs in the right lower lobe. After treatment she developed a complete lobar atelectasis and showed clinical meaningful improvement in pulmonary function and exercise capacity (FEV<sub>1</sub> +250 mL, RV -830 mL, and +61 meter on the 6MWD). One year after the initial treatment, a revision bronchoscopy was performed due to loss of treatment effect. Severe granulation tissue formation was observed and all valves were temporarily removed to allow the airways to recover. After three months, EBVs were replaced, which again resulted in a clinical meaningful benefit. One and a half year after the second EBV placement, the patient reported repeated episodes of hemoptysis. A bronchoscopy showed that this was caused by new granulation tissue formation and after a few months it was decided to permanently remove all EBVs. Subsequently, the patient underwent lung volume reduction surgery by performing a right lower lobe lobectomy via video-assisted thoracoscopy surgery with again good outcomes.

Out of the removed lung lobe four tissue samples from two different anatomical locations (both in the exact area where EBVs were previously implanted) were selected. The samples were deparaffinized, weighed, solved in 0.5mL 65% HNO<sub>3</sub>, and diluted with H<sub>2</sub>O to a total volume of 1.5mL. The nickel concentration in all four tissue samples was measured in four-fold: two baseline replicates, one replicate enriched with 10 ug/L nickel, and one replicate enriched with 20 ug/L nickel. Inductively coupled plasma mass spectrometry (ICP-MS) was used to measure the nickel concentration in each of the samples. For the reference sample, three lung tissue samples were used from a patient who was never treated with EBVs or any other lung implant and analyzed in the same manner.

The median nickel concentration in the EBV samples (0.270 µg/g, range 0.000 to 0.905) was not significantly different from the median concentration found in the reference samples (0.328 µg/g, range 0.148 to 0.542,  $p = 0.693$  [Mann-Whitney U test]) (figure 1).



**Figure 1.** Nickel concentrations in the lung tissue samples of the patient treated with EBV and the reference patient. Data are shown as individual measurements (points) and median (line). There was no significant difference in the median between both samples ( $p = 0.688$ ; Mann-Whitney U test).

## DISCUSSION

In this case-report we identified that the nickel concentration in lung tissue was similar between a patient that was previously treated with EBVs and a patient never treated with any lung implant. Furthermore, the concentrations in our study were comparable to previously published nickel concentrations in lung tissue from both cancerous and non-cancerous individuals never treated with lung implants, which ranged from 0.221 to 1.77 µg/g [189, 190]. In our analysis one of the samples showed a substantial higher nickel concentration compared to all other samples. Most likely, this is due to normal variability of the nickel concentration in the lungs, since the values were within the 'normal ranges' reported in literature.

A previous *in vitro* study found that EBVs only released a significant amount of nickel in the first 48 hours after immersion in artificial saliva[6]. If this is representative for the *in vivo* situation, it is possible that the release of nickel was already 'completed' in the patient from whom the lung tissue samples were taken and that nickel was already cleared by the immune system. However, it is likely that the *in vitro* finding is related to saturation of the used medium by nickel ions, since there is no good physiological explanation for why nickel release will end after 48 hours. Furthermore, if nickel release from EBVs does in fact stop after 48 hours of implantation, the results would have been different for new and explanted EBVs. However,

if EBVs do release a substantial amount of nickel ions and saturation of the medium was the problem with the *in vitro* experiment, nickel release will continue for a longer period of time within the lungs of a patient.

Studies testing the serum nickel concentration in patients treated with an Amplatzer septal occluder found a significant increase in the nickel concentration in serum which returned to baseline values within 3-6 months after treatment [184, 185]. It is thought that this 'normalization' of the serum nickel concentration is associated with the endothelialization of the device, because this also takes around 3-6 months. EBVs, however, are not or barely endothelialized, which will probably affect the amount of nickel released and the duration of the release. Nevertheless, it is still possible that in the first weeks or months after treatment the nickel concentration was significantly higher in lung tissue of the EBV-treated patient, which was not assessed in our study since the time between the last EBV procedure and LVRS was 27 months. It might therefore be interesting to repeat the analysis with lung tissue samples from patients in whom time between last EBV implantation and surgery is only several weeks or months, however this situation is not common in clinical practice, or to determine serum nickel concentration at multiple timepoints after EBV treatment.

In conclusion, no evidence was found for significant nickel deposition in lung tissue more than two years after treatment with EBVs. This could suggest that EBVs do not release significant amounts of nickel *in vivo* and that patients with a known nickel hypersensitivity can probably safely undergo treatment with EBVs. However, it could also be that EBVs only release nickel ions in the first period after implantation of which the duration is unknown. It might therefore be of interest to perform a prospective study to assess the nickel release from EBVs in a larger cohort using serum, sputum, bronchoalveolar lavage fluid or local biopsies to get a deeper understanding of the nickel release from implanted EBVs.

Endobronchial valve treatment does not cause significant nickel deposition in lung tissue



